SMMT

Summit Therapeutics Inc.

8.39 USD
0.00 (0.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Summit Therapeutics Inc. stock is up 86.03% since 30 days ago. The next earnings date is Aug 7, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 30% of the previous 9 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 4 PUTs, 6 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
04 Jun 13:38 21 Jun, 2024 9.00 PUT 151 2072
05 Jun 14:09 19 Jul, 2024 5.00 CALL 100 1250
06 Jun 14:09 21 Jun, 2024 8.00 PUT 426 4341
07 Jun 17:29 19 Jul, 2024 4.00 CALL 70 5564
07 Jun 17:45 21 Jun, 2024 4.00 CALL 175 2780
10 Jun 18:52 19 Jul, 2024 10.00 CALL 1000 509
10 Jun 18:52 19 Jul, 2024 7.00 PUT 1000 115
12 Jun 14:35 20 Sep, 2024 8.00 PUT 132 0
12 Jun 14:48 19 Jul, 2024 5.00 CALL 100 1250
13 Jun 19:43 19 Jul, 2024 3.00 CALL 70 446

About Summit Therapeutics Inc.

Summit Therapeutics Inc. conducts clinical programs focusing on Clostridioides difficile infection (CDI) The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is based in Cambridge, Massachusetts.

  • Stifel
    Mon Jun 3, 08:37
    buy
    confirm
  • Citigroup
    Fri May 31, 16:03
    buy
    confirm